Thomas Hellands bilde

Thomas Helland

  • E-postthomas.helland@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
  • Vis forfatter(e) (2023). Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer. 12 sider.
  • Vis forfatter(e) (2022). Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. BMJ Open.
  • Vis forfatter(e) (2021). Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer. Journal of Personalized Medicine. 1-23.
  • Vis forfatter(e) (2021). Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites. Journal of Personalized Medicine. 11 sider.
  • Vis forfatter(e) (2021). Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ breast cancer. 1-34.
  • Vis forfatter(e) (2020). Relationship between CYP2D6 genotype, tamoxifen metabolites, and adverse events, tumor biomarkers and breast cancer recurrence in a low-dose phase III trial in noninvasive disease. Journal of Clinical Oncology.
  • Vis forfatter(e) (2020). Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen. Molecular Oncology. 11 sider.
  • Vis forfatter(e) (2020). First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: A case study. ESMO Open. 1-5.
  • Vis forfatter(e) (2019). Tamoxifen in the treatment of luminal breast cancer. Implications of active metabolites on gene expression, side effects and clinical outcome.
  • Vis forfatter(e) (2019). Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.

Se fullstendig oversikt over publikasjoner i CRIStin.